Trial Outcomes & Findings for The Impact of Renin-angiotensin System on Brain Activation During Hypoglycaemia in Healthy Men, a PET Study (NCT NCT00264641)

NCT ID: NCT00264641

Last Updated: 2017-03-29

Results Overview

To compare the high RAS activity vs low RAS activity a Z score was used.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

20 participants

Primary outcome timeframe

After 4 scans on day 1

Results posted on

2017-03-29

Participant Flow

Participant milestones

Participant milestones
Measure
High RAS Activity
High RAS was defined as serum ACE and plasma angiotensinogen concentration in the highest quartiles in the population combined with AT2 receptor genotype A
Low RAS Activity
Low RAS was defined as serum ACE and plasma angiotensinogen concentration in the lowest quartiles in the population combined with AT2 receptor genotype G
Overall Study
STARTED
10
10
Overall Study
Initiation of the Study
10
10
Overall Study
COMPLETED
10
10
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The Impact of Renin-angiotensin System on Brain Activation During Hypoglycaemia in Healthy Men, a PET Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
High RAS Activity
n=10 Participants
High RAS activity is defined in the protocol
Low RAS Activity
n=10 Participants
Low RAS activity is defined in the protocol
Total
n=20 Participants
Total of all reporting groups
Age, Continuous
26 years
STANDARD_DEVIATION 4.8 • n=5 Participants
27 years
STANDARD_DEVIATION 5.6 • n=7 Participants
26.5 years
STANDARD_DEVIATION 5.2 • n=5 Participants
Sex: Female, Male
Female
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Sex: Female, Male
Male
10 Participants
n=5 Participants
10 Participants
n=7 Participants
20 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
White
10 Participants
n=5 Participants
10 Participants
n=7 Participants
20 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
Denmark
10 participants
n=5 Participants
10 participants
n=7 Participants
20 participants
n=5 Participants

PRIMARY outcome

Timeframe: After 4 scans on day 1

Population: Only data available is between group analysis

To compare the high RAS activity vs low RAS activity a Z score was used.

Outcome measures

Outcome measures
Measure
All Study Participants
n=20 Participants
From a screening population ten subjects with high RAS activity - defined as serum ACE and plasma angiotensinogen concentrations in the highest quartile in the population combined with presence of AT2 receptor genotype A corresponding to low expression of the receptor (maximum stimulation via the AT1 receptor) - were selected And 10 males with low RAS activity - defined as serum ACE and plasma angiotensinogen concentrations in the lowest quartile in the population combined with the presence of AT2 receptor genotype G corresponding to high expression of the receptor (58) (minimum stimulation via the AT1 receptor) were selected
Cerebral Activation During Hypoglycaemia
High RAS>Low RAS post entorhinal cortex
4.55 Z score
Cerebral Activation During Hypoglycaemia
Low RAS>High RAS Right sup frontal gyrus
4.85 Z score

Adverse Events

High RAS Activity

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Low RAS Activity

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Prof. Birger Thorsteinsson

Hypoglycaemia Research Group

Phone: +4548294829

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place